The present study suggests the clinical utility of PAM50 ROR scores for predicting the prognosis in Japanese postmenopausal patients with ER-positive, HER2-negative early breast cancer, based on long-term follow-up data. This evidence concerns the gene ERBB2 and breast carcinoma.